Amarin Corporation PLC Plunges After Lead Drug Is Dealt Another Setback; Stock Down -11.51% At Market Close (November 22, 2013)

Published: Nov 22, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Amarin Corp Plc said the U.S. Food and Drug Administration did not accept its appeal for the review of a regulatory decision to revoke an agreement related to the trial of its lead drug that lowers a type of blood fat. Amarin said on Oct. 29 that the FDA rescinded the agreement which guaranteed that the design of a late-stage trial of Amarin's triglyceride-lowering drug Vascepa was adequate to support a marketing application. The trial, Anchor, was testing Vascepa in patients who also take a cholesterol-lowering statin such as Pfizer Inc's Lipitor and are at a high risk of coronary heart disease.

Help employers find you! Check out all the jobs and post your resume.

Back to news